Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers
Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer...
Gespeichert in:
Veröffentlicht in: | Pharmaceutical research 2007-07, Vol.24 (7), p.1336-1345 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1345 |
---|---|
container_issue | 7 |
container_start_page | 1336 |
container_title | Pharmaceutical research |
container_volume | 24 |
creator | MAHER, Sam FEIGHERY, Linda BRAYDEN, David J MCCLEAN, Siobhan |
description | Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2.
The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors.
Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling.
Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins. |
doi_str_mv | 10.1007/s11095-007-9288-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20725578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20725578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</originalsourceid><addsrcrecordid>eNp1kU-LFDEQxYMo7uzqB_AiQVlvWVNJp5Pemyz-GVjxouAtpDOJm6U7mU16hPn21jgDC4KnFFW_evXII-QV8CvgXL9vAHxQDEs2CGOYeEJWoLRkA-9-PiUrrkXHjO7gjJy3ds85NzB0z8kZaKml0t2KPHwNU1qWlKlr1GUatmm5w5ab6DbUObgx4XxPQ75z2Yd6RdfXdJ1_h7akX25JJdMSaVoanYNHJLX50HD-7whlvfOFCTqXXCa3D7W9IM-im1p4eXovyI9PH7_ffGG33z6vbz7cMt8ZWJg2o-E9moxxiHrYSDmGTSf63geIzoAeAUS_0Xr0chBRG4cLIPWoRqW4CPKCvDvqbmt52KFfO6fmwzS5HMquWYG_o5Q2CL79B7wvu5rRm8VzCtW1AKTe_JcSyEmlJEJwhHwtrdUQ7bam2dW9BW4PkdljZPZQHiKzAnden4R34xw2jxunjBC4PAGueTfFikGk9sgZ0xvoBvkHbC6dZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222663553</pqid></control><display><type>article</type><title>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>MAHER, Sam ; FEIGHERY, Linda ; BRAYDEN, David J ; MCCLEAN, Siobhan</creator><creatorcontrib>MAHER, Sam ; FEIGHERY, Linda ; BRAYDEN, David J ; MCCLEAN, Siobhan</creatorcontrib><description>Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2.
The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors.
Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling.
Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-007-9288-2</identifier><identifier>PMID: 17373574</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Actin ; Actins - metabolism ; Antimicrobial peptides ; Aristolochic acid ; Aristolochic Acids - pharmacology ; Biological and medical sciences ; Caco-2 Cells ; Cadherins - metabolism ; Cell Survival - drug effects ; Cellular biology ; Cyclooxygenase Inhibitors - pharmacology ; Cytotoxicity ; Dextrans - chemistry ; Dextrans - metabolism ; Dose-Response Relationship, Drug ; E-cadherin ; Electric Impedance ; Electrical resistivity ; Enzyme Inhibitors - pharmacology ; Fluorescein-5-isothiocyanate - analogs & derivatives ; Fluorescein-5-isothiocyanate - chemistry ; Fluorescein-5-isothiocyanate - metabolism ; Fluorescent indicators ; Gene expression ; General pharmacology ; Humans ; Immunofluorescence ; Indomethacin ; Indomethacin - pharmacology ; Intestinal Absorption - drug effects ; Intestinal Mucosa - drug effects ; Intestinal Mucosa - metabolism ; Mannitol ; Medical sciences ; Melitten - pharmacology ; Membrane Proteins - metabolism ; Molecular Weight ; Peptides ; Permeability ; Permeability - drug effects ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology ; Pharmacology. Drug treatments ; Phospholipase A2 ; Phospholipases A - antagonists & inhibitors ; Phospholipases A - metabolism ; Phospholipases A2 ; Phosphoproteins - metabolism ; Piroxicam ; Piroxicam - pharmacology ; Prostaglandin endoperoxide synthase ; Prostaglandin-Endoperoxide Synthases - metabolism ; Prostaglandins - metabolism ; Proteins ; Signal Transduction - drug effects ; Tight junctions ; Tight Junctions - drug effects ; Tight Junctions - metabolism ; Time Factors ; Western blotting ; Zonula Occludens-1 Protein</subject><ispartof>Pharmaceutical research, 2007-07, Vol.24 (7), p.1336-1345</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC 2007</rights><rights>Springer Science+Business Media, LLC 2007.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</citedby><cites>FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18868149$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17373574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAHER, Sam</creatorcontrib><creatorcontrib>FEIGHERY, Linda</creatorcontrib><creatorcontrib>BRAYDEN, David J</creatorcontrib><creatorcontrib>MCCLEAN, Siobhan</creatorcontrib><title>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2.
The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors.
Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling.
Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins.</description><subject>Actin</subject><subject>Actins - metabolism</subject><subject>Antimicrobial peptides</subject><subject>Aristolochic acid</subject><subject>Aristolochic Acids - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Caco-2 Cells</subject><subject>Cadherins - metabolism</subject><subject>Cell Survival - drug effects</subject><subject>Cellular biology</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Cytotoxicity</subject><subject>Dextrans - chemistry</subject><subject>Dextrans - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>E-cadherin</subject><subject>Electric Impedance</subject><subject>Electrical resistivity</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fluorescein-5-isothiocyanate - analogs & derivatives</subject><subject>Fluorescein-5-isothiocyanate - chemistry</subject><subject>Fluorescein-5-isothiocyanate - metabolism</subject><subject>Fluorescent indicators</subject><subject>Gene expression</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Immunofluorescence</subject><subject>Indomethacin</subject><subject>Indomethacin - pharmacology</subject><subject>Intestinal Absorption - drug effects</subject><subject>Intestinal Mucosa - drug effects</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Mannitol</subject><subject>Medical sciences</subject><subject>Melitten - pharmacology</subject><subject>Membrane Proteins - metabolism</subject><subject>Molecular Weight</subject><subject>Peptides</subject><subject>Permeability</subject><subject>Permeability - drug effects</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phospholipase A2</subject><subject>Phospholipases A - antagonists & inhibitors</subject><subject>Phospholipases A - metabolism</subject><subject>Phospholipases A2</subject><subject>Phosphoproteins - metabolism</subject><subject>Piroxicam</subject><subject>Piroxicam - pharmacology</subject><subject>Prostaglandin endoperoxide synthase</subject><subject>Prostaglandin-Endoperoxide Synthases - metabolism</subject><subject>Prostaglandins - metabolism</subject><subject>Proteins</subject><subject>Signal Transduction - drug effects</subject><subject>Tight junctions</subject><subject>Tight Junctions - drug effects</subject><subject>Tight Junctions - metabolism</subject><subject>Time Factors</subject><subject>Western blotting</subject><subject>Zonula Occludens-1 Protein</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU-LFDEQxYMo7uzqB_AiQVlvWVNJp5Pemyz-GVjxouAtpDOJm6U7mU16hPn21jgDC4KnFFW_evXII-QV8CvgXL9vAHxQDEs2CGOYeEJWoLRkA-9-PiUrrkXHjO7gjJy3ds85NzB0z8kZaKml0t2KPHwNU1qWlKlr1GUatmm5w5ab6DbUObgx4XxPQ75z2Yd6RdfXdJ1_h7akX25JJdMSaVoanYNHJLX50HD-7whlvfOFCTqXXCa3D7W9IM-im1p4eXovyI9PH7_ffGG33z6vbz7cMt8ZWJg2o-E9moxxiHrYSDmGTSf63geIzoAeAUS_0Xr0chBRG4cLIPWoRqW4CPKCvDvqbmt52KFfO6fmwzS5HMquWYG_o5Q2CL79B7wvu5rRm8VzCtW1AKTe_JcSyEmlJEJwhHwtrdUQ7bam2dW9BW4PkdljZPZQHiKzAnden4R34xw2jxunjBC4PAGueTfFikGk9sgZ0xvoBvkHbC6dZA</recordid><startdate>20070701</startdate><enddate>20070701</enddate><creator>MAHER, Sam</creator><creator>FEIGHERY, Linda</creator><creator>BRAYDEN, David J</creator><creator>MCCLEAN, Siobhan</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20070701</creationdate><title>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</title><author>MAHER, Sam ; FEIGHERY, Linda ; BRAYDEN, David J ; MCCLEAN, Siobhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Actin</topic><topic>Actins - metabolism</topic><topic>Antimicrobial peptides</topic><topic>Aristolochic acid</topic><topic>Aristolochic Acids - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Caco-2 Cells</topic><topic>Cadherins - metabolism</topic><topic>Cell Survival - drug effects</topic><topic>Cellular biology</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Cytotoxicity</topic><topic>Dextrans - chemistry</topic><topic>Dextrans - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>E-cadherin</topic><topic>Electric Impedance</topic><topic>Electrical resistivity</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fluorescein-5-isothiocyanate - analogs & derivatives</topic><topic>Fluorescein-5-isothiocyanate - chemistry</topic><topic>Fluorescein-5-isothiocyanate - metabolism</topic><topic>Fluorescent indicators</topic><topic>Gene expression</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Immunofluorescence</topic><topic>Indomethacin</topic><topic>Indomethacin - pharmacology</topic><topic>Intestinal Absorption - drug effects</topic><topic>Intestinal Mucosa - drug effects</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Mannitol</topic><topic>Medical sciences</topic><topic>Melitten - pharmacology</topic><topic>Membrane Proteins - metabolism</topic><topic>Molecular Weight</topic><topic>Peptides</topic><topic>Permeability</topic><topic>Permeability - drug effects</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phospholipase A2</topic><topic>Phospholipases A - antagonists & inhibitors</topic><topic>Phospholipases A - metabolism</topic><topic>Phospholipases A2</topic><topic>Phosphoproteins - metabolism</topic><topic>Piroxicam</topic><topic>Piroxicam - pharmacology</topic><topic>Prostaglandin endoperoxide synthase</topic><topic>Prostaglandin-Endoperoxide Synthases - metabolism</topic><topic>Prostaglandins - metabolism</topic><topic>Proteins</topic><topic>Signal Transduction - drug effects</topic><topic>Tight junctions</topic><topic>Tight Junctions - drug effects</topic><topic>Tight Junctions - metabolism</topic><topic>Time Factors</topic><topic>Western blotting</topic><topic>Zonula Occludens-1 Protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAHER, Sam</creatorcontrib><creatorcontrib>FEIGHERY, Linda</creatorcontrib><creatorcontrib>BRAYDEN, David J</creatorcontrib><creatorcontrib>MCCLEAN, Siobhan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAHER, Sam</au><au>FEIGHERY, Linda</au><au>BRAYDEN, David J</au><au>MCCLEAN, Siobhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>2007-07-01</date><risdate>2007</risdate><volume>24</volume><issue>7</issue><spage>1336</spage><epage>1345</epage><pages>1336-1345</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2.
The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors.
Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling.
Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>17373574</pmid><doi>10.1007/s11095-007-9288-2</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0724-8741 |
ispartof | Pharmaceutical research, 2007-07, Vol.24 (7), p.1336-1345 |
issn | 0724-8741 1573-904X |
language | eng |
recordid | cdi_proquest_miscellaneous_20725578 |
source | MEDLINE; SpringerLink Journals |
subjects | Actin Actins - metabolism Antimicrobial peptides Aristolochic acid Aristolochic Acids - pharmacology Biological and medical sciences Caco-2 Cells Cadherins - metabolism Cell Survival - drug effects Cellular biology Cyclooxygenase Inhibitors - pharmacology Cytotoxicity Dextrans - chemistry Dextrans - metabolism Dose-Response Relationship, Drug E-cadherin Electric Impedance Electrical resistivity Enzyme Inhibitors - pharmacology Fluorescein-5-isothiocyanate - analogs & derivatives Fluorescein-5-isothiocyanate - chemistry Fluorescein-5-isothiocyanate - metabolism Fluorescent indicators Gene expression General pharmacology Humans Immunofluorescence Indomethacin Indomethacin - pharmacology Intestinal Absorption - drug effects Intestinal Mucosa - drug effects Intestinal Mucosa - metabolism Mannitol Medical sciences Melitten - pharmacology Membrane Proteins - metabolism Molecular Weight Peptides Permeability Permeability - drug effects Pharmaceutical technology. Pharmaceutical industry Pharmacology Pharmacology. Drug treatments Phospholipase A2 Phospholipases A - antagonists & inhibitors Phospholipases A - metabolism Phospholipases A2 Phosphoproteins - metabolism Piroxicam Piroxicam - pharmacology Prostaglandin endoperoxide synthase Prostaglandin-Endoperoxide Synthases - metabolism Prostaglandins - metabolism Proteins Signal Transduction - drug effects Tight junctions Tight Junctions - drug effects Tight Junctions - metabolism Time Factors Western blotting Zonula Occludens-1 Protein |
title | Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A56%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melittin%20as%20an%20epithelial%20permeability%20enhancer.%20I:%20Investigation%20of%20its%20mechanism%20of%20action%20in%20caco-2%20monolayers&rft.jtitle=Pharmaceutical%20research&rft.au=MAHER,%20Sam&rft.date=2007-07-01&rft.volume=24&rft.issue=7&rft.spage=1336&rft.epage=1345&rft.pages=1336-1345&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1007/s11095-007-9288-2&rft_dat=%3Cproquest_cross%3E20725578%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222663553&rft_id=info:pmid/17373574&rfr_iscdi=true |